Peptide Comparison
PemvidutidevsRetatrutide
Balanced dual GLP-1/glucagon receptor agonist with no dose titration required and breakthrough therapy designation for MASH.
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials.
At a Glance
Quick
comparison
Dose Range
Pemvidutide
1.2 mg–2.4 mg mg
Retatrutide
1–12 mg
Frequency
Pemvidutide
Once daily
Retatrutide
Once weekly
Administration
Pemvidutide
Subcutaneous injection
Retatrutide
Subcutaneous injection
Cycle Length
Pemvidutide
Ongoing/indefinite
Retatrutide
12+ weeks
Onset Speed
Pemvidutide
Moderate (1-2 weeks)
Retatrutide
Moderate (1-2 weeks)
Evidence Level
Pemvidutide
Moderate human trials (Phase 1-2)
Retatrutide
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Weight Loss
Liver Health
Metabolic Health
Weight Loss Power
Appetite Control
Technical Data
Compound
specifications
Pemvidutide
Molecular Formula
C182H275N39O54
Molecular Weight
3873.35 Da
Half-Life
Approximately 110 hours (4.6 days)
Bioavailability
Subcutaneous bioavailability consistent with glycolipid-conjugated peptide therapeutics
CAS Number
2538014-94-5
Retatrutide
Molecular Formula
C221H342N46O68
Molecular Weight
4731 g/mol
Half-Life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
CAS Number
2381089-83-2
Protocols
Dosing
tiers
Pemvidutide
Retatrutide
Applications
Best
suited for
Pemvidutide
Adults seeking substantial weight loss without complex dose titration
Pemvidutide is particularly well-suited for individuals focused on adults seeking substantial weight loss without complex dose titration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
Pemvidutide is particularly well-suited for individuals focused on individuals with concurrent mash/nafld and obesity requiring dual-target therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with metabolic syndrome who need comprehensive risk factor improvement
Pemvidutide is particularly well-suited for individuals focused on patients with metabolic syndrome who need comprehensive risk factor improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those interested in investigational dual agonist therapies with strong early data
Pemvidutide is particularly well-suited for individuals focused on those interested in investigational dual agonist therapies with strong early data. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Retatrutide
Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs. No other medication has matched this.
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously.
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Safety Profile
Side
effects
Pemvidutide
Common
- Nausea
- Diarrhea
- Headache
Uncommon
- Vomiting
- Decreased Appetite
Serious
- Acute Pancreatitis
- Severe Gastrointestinal Disturbance
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Research Status
Safety
& evidence
Pemvidutide
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Pemvidutide (rzenx, Eli Lilly GLP-1/GCG dual agonist) completed Phase IIb obesity trials with favorable cardiovascular safety profile. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of subjects, more prominent than GLP-1 monotherapy due to GCG receptor activation. Pancreatitis risk and elevated calcitonin levels require monitoring. No serious cardiac safety signals despite dual receptor activation; heart rate increases of 5-10 bpm observed.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma or MEN2 syndrome
- xKnown hypersensitivity to pemvidutide or formulation components
- xHistory of acute pancreatitis
- xSevere hepatic decompensation (Child-Pugh C cirrhosis)
Retatrutide
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants. Most side effects are gastrointestinal and tend to improve over time. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (MTC)
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- xPregnancy or planning to become pregnant
- xHistory of severe pancreatitis
- xKnown allergy to GLP-1 receptor agonists
Decision Guide
Which is
right for you?
Choose Pemvidutide if...
- Adults seeking substantial weight loss without complex dose titration
- Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
- Patients with metabolic syndrome who need comprehensive risk factor improvement
- Those interested in investigational dual agonist therapies with strong early data
Choose Retatrutide if...
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization